Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial
Benjamin A. Fisher(Birmingham City University), Pamela Kearns(National Institute for Health and Care Research), Tonny Veenith(New Cross Hospital), Charlotte Gaskell(Cancer Research UK Clinical Trials Unit), David Thickett(Centre for Inflammation Research), Julian Bion(Clinical Trial Investigators), Matthew Rowland(University of Oxford), Dhruv Parekh(University Hospitals Birmingham NHS Foundation Trust), Philip N. Newsome(King's College London), James Scriven(University Hospitals Birmingham NHS Foundation Trust), Rowena Sharpe(Cancer Research UK Clinical Trials Unit), Duncan Richards(University of Oxford), Matt P. Wise(University Hospital of Wales), Graham Cooke(St Mary's Hospital), Daniel Slade(Temple University), Joanna C. Porter(University College Hospital), Anna Rowe(University Hospitals Birmingham NHS Foundation Trust), Ling‐Pei Ho(University of Oxford), Helen McShane(University of Oxford), Madhu Balasubramaniam(Royal Bolton Hospital), Simon Gates(Oxford Brookes University), Zoë Gabriel(Sheffield Teaching Hospitals NHS Foundation Trust), Tony Whitehouse(Queen Elizabeth Hospital Birmingham)
Cited by 7
Related Papers
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
|Intensive Care Medicine|2007|4.9k
Interventions for preventing falls in older people living in the community
|Cochrane Database of Systematic Reviews|2012|3.9k
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008
|Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)|2008|3.9k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k
The Global Burden of Cancer 2013
|JAMA Oncology|2015|2.8k